Revascular Bio Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Revascular Bio General Information

Description

Developer of an angiogenesis cell therapy designed to address intractable diseases. The company offers to deliver endothelial stem cells as pharmaceuticals to treat chronic wounds, such as intractable skin ulcers, severe lower limb ischemia, and cerebrovascular dementia, enabling medical staff to enhance the lives of patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3-1 Yamadaoka, Suita
  • Osaka, 565-0871
  • Japan
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 3-1 Yamadaoka, Suita
  • Osaka, 565-0871
  • Japan

Revascular Bio Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Revascular Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 05-Mar-2024 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
2. Seed Round 10-Nov-2023 $1.47M $1.67M Completed Generating Revenue
1. Accelerator/Incubator 01-Nov-2023 $200K $200K Completed Generating Revenue
To view Revascular Bio’s complete valuation and funding history, request access »

Revascular Bio Patents

Revascular Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260347793-A1 Method for producing high-purity vascular endothelial cell population from biological tissue or organ Pending 15-May-2023
WO-2024237278-A1 Method for producing high-purity vascular endothelial cell population from biological tissue or organ Inactive 15-May-2023

Revascular Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Revascular Bio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kansai Startup Incubation Accelerator/Incubator
Intellectual Property Acceleration Program for Startups Accelerator/Incubator
Osaka University Venture Capital Corporate Venture Capital Minority
Berkeley SkyDeck Accelerator/Incubator Minority
To view Revascular Bio’s complete investors history, request access »

Revascular Bio FAQs

  • When was Revascular Bio founded?

    Revascular Bio was founded in 2022.

  • Where is Revascular Bio headquartered?

    Revascular Bio is headquartered in Osaka, Japan.

  • What is the size of Revascular Bio?

    Revascular Bio has 9 total employees.

  • What industry is Revascular Bio in?

    Revascular Bio’s primary industry is Drug Delivery.

  • Is Revascular Bio a private or public company?

    Revascular Bio is a Private company.

  • What is Revascular Bio’s current revenue?

    The current revenue for Revascular Bio is .

  • How much funding has Revascular Bio raised over time?

    Revascular Bio has raised $1.67M.

  • Who are Revascular Bio’s investors?

    Kansai Startup Incubation, Intellectual Property Acceleration Program for Startups, Osaka University Venture Capital, and Berkeley SkyDeck have invested in Revascular Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process